Stockreport

Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA dur [Read more]